Skip to main content
Premium Trial:

Request an Annual Quote

Centogene Regains Compliance With Nasdaq Listing Requirements

NEW YORK — Centogene said on Friday that it has been notified by the Nasdaq that the company has regained compliance with the stock exchange's minimum bid price requirement and minimum market value of publicly held shares (MVPHS) requirement.

In April, the German firm disclosed that it failed to meet the requirement that its shares close with a bid price of at least $1 for 30 consecutive trading days. A couple of months later, it received notification that it had also failed to maintain a minimum MVPHS of $15 million for 30 consecutive business days as required by the Nasdaq.

The company had already regained compliance with Nasdaq's requirements once before this year, after missing the minimum bid price requirement last December.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.